When is hormone therapy recommended for ductal carcinoma in situ?

Ductal carcinoma in situ is a non-invasive change confined to the milk ducts. Pathology testing can identify hormone receptors in the abnormal cells. If receptors are present, hormone therapy may reduce hormone stimulation in breast tissue. It does not replace the local treatment recommended for the area, and it is not used in the same way for every person. The discussion can depend on the operation performed, whether breast tissue remains, menopausal status, and personal health factors.

Review the pathology report with the breast team, including receptor results and the margins from surgery. Ask what the medicine is intended to prevent, how it would fit with surgery or radiotherapy, and which side effects need monitoring. Tell the team about blood-clot history, bone problems, abnormal bleeding, or medicines you already take. Further information is available in Hormone Therapy for Cancer.

Report a new breast change, wound problem, fever, or unusual discharge to the treating team. While taking hormone therapy, seek urgent help for sudden breathlessness, chest pain, coughing blood, or a swollen painful leg. Contact the clinic about troublesome hot flushes, joint pain, mood changes, or unexpected vaginal bleeding.

Ask whether the DCIS is hormone-receptor positive, whether treatment is optional or strongly advised in your situation, what benefit is expected, how long it may be used, and what other approaches could be considered.